Nucleoside-modified messenger RNA COVID-19 vaccine platform.

Roncati, Luca; Corsi, Lorenzo

Roncati, Luca; Corsi, Lorenzo.

Affiliation

Roncati L; Department of Surgery, Medicine, Dentistry and Morphological Sciences with interest in Transplantation, Oncology and Regenerative Medicine, Institute of Pathology, University of Modena and Reggio Emilia, Modena, Italy.
Corsi L; Department of Life Sciences, Section of Pharmacology, University of Modena and Reggio Emilia, Modena, Italy.

J Med Virol ; 93(7): 4054-4057, 2021 Jul.

Article in En | MEDLINE | ID: mdl-33675239

Subject(s)

COVID-19 Vaccines; COVID-19/prevention & control; Vaccines, Synthetic; 2019-nCoV Vaccine mRNA-1273; BNT162 Vaccine; COVID-19 Vaccines/administration & dosage; COVID-19 Vaccines/adverse effects; COVID-19 Vaccines/immunology; Humans; Hypersensitivity/etiology; Liposomes/adverse effects; Nanoparticles/adverse effects; Nucleosides; Pandemics/prevention & control; Pharmacovigilance; Polyethylene Glycols/adverse effects; RNA, Messenger/chemistry; Vaccines, Synthetic/administration & dosage; Vaccines, Synthetic/adverse effects; Vaccines, Synthetic/immunology; mRNA Vaccines

Key words

coronavirus disease 2019; hypersensitivity; nucleoside-modified messenger RNA; severe acute respiratory syndrome coronavirus 2; vaccine

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Vaccines, Synthetic / COVID-19 Vaccines / COVID-19 Type of study: Etiology_studies Limits: Humans Language: En Journal: J Med Virol Year: 2021 Document type: Article Affiliation country: Italy

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google